.png){kind=icon}
返回
INTERFERON THERAPY FOR BEHCETS-DISEASE
.png){kind=icon}
PRE
AI
DOI：10.1016/S0190-9622(94)70226-8.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Background: Behcet's disease was first described in 1937 as a trisymptom complex. No standard therapy has been established. Tts cause is presumed to be viral or immunologic. Objective: We sought to determine whether patients with Behcet's disease benefit from interferon, which has antiviral, immunomodulatory, antiproliferative, and antitumoral properties. Methods: Fourteen patients were initially given 3 MU interferon alfa-2a subcutaneously three times per week. The doses were gradually increased to 12 MU. Each patient received a total dose of 216 MU during the 2-month study. Therapy with 9 MU interferon alfa-2a once a month was continued in half the patients. Ah patients were observed before and after treatment for 6-month periods, and all symptoms were recorded. Results: All patients were symptom free by the end of the 2-month treatment period. The frequencies of oral and genital ulcers as well as pustular vasculitis decreased significantly in the posttreatment period as compared with the pretreatment period. Conclusion: The data suggest that interferon treatment appears to be effective for patients with Behcet's disease.
Keyword:
GAMMA
期刊
IF:
11.8
论文数:
2.6W
被引数:
3.9W
机构
暂无机构信息
引用论文
Synthesis of electron-deficient oxetanes. 3-Azidooxetane, 3-nitrooxetane, and 3,3-dinitrooxetane
.png){kind=icon}
PREAI
分享收藏
分享收藏 没有更多内容
没有更多内容